CDC and RFK Jr.'s Panel Endorse Merck's RSV Vaccine for Infants
TL;DR Summary
CDC vaccine advisers recommend Merck’s new monoclonal antibody, Enflonsia, for infants under 8 months to prevent RSV, showing significant effectiveness in reducing hospitalizations, though the recommendation awaits final approval amid some debate over clinical trial data.
- CDC vaccine advisers recommend Merck’s RSV therapy for babies STAT
- CDC vaccine advisory panel to study child immunization schedule, recommends RSV shot for babies ABC News - Breaking News, Latest News and Videos
- In surprise move, RFK Jr.'s vaccine committee votes to recommend RSV shot for infants USA Today
- ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season Merck.com
- RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants CNBC
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
4 min
vs 4 min read
Condensed
95%
798 → 36 words
Want the full story? Read the original article
Read on STAT